Bio-Rad Laboratories, Inc. (BIO)
| Market Cap | 15.06B |
| Revenue (ttm) | 2.90B |
| Net Income (ttm) | -101.13M |
| Shares Out | 29.65M |
| EPS (ttm) | -3.39 |
| PE Ratio | n/a |
| Forward PE | 37.88 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 171,276 |
| Open | 509.94 |
| Previous Close | 505.58 |
| Day's Range | 502.71 - 511.89 |
| 52-Week Range | 462.61 - 832.70 |
| Beta | 0.92 |
| Analysts | Buy |
| Price Target | 725.90 (+42.9%) |
| Earnings Date | Aug 4, 2022 |
About BIO
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics,... [Read more...]
Financial Performance
In 2021, BIO's revenue was $2.92 billion, an increase of 14.81% compared to the previous year's $2.55 billion. Earnings were $4.25 billion, an increase of 11.55%.
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for BIO stock is "Buy." The 12-month stock price forecast is 725.9, which is an increase of 42.94% from the latest price.
News
Here's Why You Should Invest in Bio-Rad (BIO) Stock Now
Investors are optimistic about Bio-Rad's (BIO) strong growth in its key product lines across several geographies.
Bio-Rad (BIO) Immunohematology Arm Recovers, New Launches Aid
Bio-Rad's (BIO) qPCR business is experiencing excellent uptake from the new-generation CFX Opus platform.
Wall Street Analysts Believe Bio-Rad (BIO) Could Rally 53%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 52.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positive ...
Bio-Rad (BIO) Q1 Earnings Surpass Estimates, Margins Up
Bio-Rad's (BIO) first-quarter 2022 revenues decline year over year due to lower COVID-related demand.
Bio-Rad Laboratories (BIO) Surpasses Q1 Earnings and Revenue Estimates
Bio-Rad (BIO) delivered earnings and revenue surprises of 76.43% and 3.25%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Reports First-Quarter 2022 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the f...
Medical Products Stocks' Earnings on Apr 28: TMO, BIO & More
Medical Products companies' results are likely to reflect a rebound in the base business. Let's see how TMO, BIO, LH and RMD fare this time.
Here's Why You Should Retain Bio-Rad (BIO) Stock For Now
Investors are optimistic about Bio-Rad (BIO) owing to a recovery in most of its key global markets as well as an uptick in demand for COVID-related products.
Bio-Rad to Report First-Quarter Financial Results, Thursday, April 28, 2022
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the first...
Bio-Rad (BIO) Thrives on Global Sales and Testing Uptake
Bio-Rad's (BIO) underlying Life Science business' core revenues grow on strong uptake of Droplet Digital PCR as well as the qPCR business.
Bio-Rad (BIO) Loses 15.1% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Bio-Rad (BIO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earn...
Bio-Rad's (BIO) Product Launches Aid Growth, Global Arm Strong
Bio-Rad's (BIO) Diagnostics business registers growth across all its product lines, driven by the recovery of routine testing.
Bio-Rad Announces Closing of $1.2 Billion Aggregate Senior Notes Offering
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today the closing of its underwri...
Bio-Rad Presents Growth Strategy and Acceleration of Financial Targets at Investor Day
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, is hosting an in-person investor day beginn...
All Hail the Balance Sheet Powerhouses
For the past half dozen years, investors couldn't care less about a company's balance sheet.
Wall Street Analysts Think Bio-Rad (BIO) Could Surge 42%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 41.9% in Bio-Rad (BIO). While the effectiveness of this highly sought-after metric is questionable, the positive ...
Bio-Rad (BIO) Q4 Earnings Surpass Estimates, Margins Down
Strength in Life Sciences segment driven by a recovery in routine testing drove Bio-Rad (BIO) top line in the fourth quarter.
Bio-Rad Laboratories (BIO) Q4 Earnings Top Estimates
Bio-Rad (BIO) delivered earnings and revenue surprises of 11.85% and 0.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Bio-Rad Reports Fourth-Quarter and Full-Year 2021 Financial Results
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the f...
Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline
Bio-Rad (BIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bio-Rad to Host Investor Day on February 25
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, announced today that it will host an in-per...
Bio-Rad to Report Fourth-Quarter and Full-Year 2021 Financial Results, Thursday, February 10, 2022
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, will report financial results for the fourt...
Bio Rad's (BIO) Product Launches Aid, Forex Woes Persist
Bio Rad's (BIO) strength in its key product lines across major geographic regions buoys optimism.